{"nctId":"NCT01569841","briefTitle":"A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes","startDateStruct":{"date":"2012-04"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"count":24,"armGroups":[{"label":"IDeg","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]},{"label":"IGlar","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin glargine"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin glargine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 1 diabetes\n* HbA1c (glycosylated haemoglobin) below or equal to 8.5%\n* Current treatment with IGlar (insulin glargine) in a basal-bolus regimen with a total daily dose below 120 U\n* BMI (body mass index) below 35 kg/m\\^2\n\nExclusion Criteria:\n\n* Use within the last 3 months prior to visit 1 (screening) of any antidiabetic glucose lowering drug other than insulin/insulin analogues\n* Subjects with regular use of acetaminophen who are not willing to use another analgetic during CGM (Continuous Glucose Monitoring) periods\n* Stroke; heart failure; myocardial infarction; unstable angina pectoris; coronary arterial bypass graft or angioplasty within 24 weeks prior to visit 1\n* Recurrent severe hypoglycemia (more than one severe hypoglycemic event during the last 12 months) or hypoglycemia unawareness or hospitalization for diabetic ketoacidosis during the previous 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL)","description":"Time within the glycaemic target range \\[\\> 70 mg/dL (3.9 mmol/L) and \\< 130 mg/dL (7.2 mmol/L)\\] measured by Continuous Glucose Monitoring (CGM) in the last four hours of each dosing interval during the last 2 weeks of the 6-week treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":"0.71"},{"groupId":"OG001","value":"1.09","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Mean Interstitial Glucose (IG) Based on 14 Days of CGM","description":"The observed mean of IG profile was obtained as the average value of area under the IG profile divided by the actual assessment time interval during the last 2 weeks of the 6-week treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"1.5"},{"groupId":"OG001","value":"9.8","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG)","description":"FPG after 6 weeks of treatment in each treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"4.6"},{"groupId":"OG001","value":"10.9","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"3.4"},{"groupId":"OG001","value":"10.9","spread":"4.4"}]}]}]},{"type":"SECONDARY","title":"Glycosylated Haemoglobin (HbA1c)","description":"HbA1c after 6 weeks of treatment in each treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.5"},{"groupId":"OG001","value":"7.1","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"0.7"},{"groupId":"OG001","value":"7.3","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Adverse Events (AEs)","description":"Number of treatment emergent adverse events (TEAEs). An AE was defined as treatment emergent if the onset date was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Confirmed Hypoglycaemic Episodes","description":"A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of investigational medicinal product (IMP), and no later than 7 days after the last day on trial product. Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia or minor hypoglycaemic episodes. Severe hypoglycaemic episodes: requiring assistance to administer carbohydrate, glucagon or other resuscitative actions. Minor hypoglycaemic episodes: able to treat her/himself and plasma glucose below 3.1 mmol/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"283","spread":null},{"groupId":"OG001","value":"239","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["Nasopharyngitis"]}}}